US 12,239,656 B2
Nucleoporins as drug targets for anti-proliferative therapeutics
Maximiliano D'Angelo, San Diego, CA (US)
Assigned to SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, La Jolla, CA (US)
Filed by Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US)
Filed on Nov. 22, 2022, as Appl. No. 18/058,212.
Application 18/058,212 is a continuation of application No. 16/629,463, granted, now 11,564,937, previously published as PCT/US2018/041461, filed on Jul. 10, 2018.
Claims priority of provisional application 62/531,257, filed on Jul. 11, 2017.
Prior Publication US 2023/0172964 A1, Jun. 8, 2023
Int. Cl. C07H 21/02 (2006.01); A61K 31/7105 (2006.01); A61K 35/00 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); G01N 33/50 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/7105 (2013.01) [A61K 35/00 (2013.01); C12N 15/113 (2013.01); G01N 33/5011 (2013.01); A61K 45/06 (2013.01); C12N 2310/122 (2013.01); C12N 2310/141 (2013.01)] 13 Claims
 
1. A method of treating a proliferative disease or disorder in an individual in need thereof, the method comprising:
administering to the individual a therapeutically effective amount of an agent that inhibits nuclear pore complex assembly or induces nuclear pore complex disassembly, wherein the nuclear pore complex assembly is not inhibited in non-dividing cells or the nuclear pore complex disassembly is not induced in the non-dividing cells, wherein the proliferative disease or disorder is cancer, wherein the cancer has a mutation in a Ras gene, wherein the agent is a small interfering RNA (siRNA) or short hairpin RNA (shRNA), and wherein the agent targets one or more of Nup93 or Nup96 of a nuclear pore complex.